A Phase 1 Clinical Trial of Cirmtuzumab, a First-in-Class ROR1 Inhibiting Antibody, for the Treatment of Patients with Relapsed or Refractory CLL: Interim Analysis
Titel:
A Phase 1 Clinical Trial of Cirmtuzumab, a First-in-Class ROR1 Inhibiting Antibody, for the Treatment of Patients with Relapsed or Refractory CLL: Interim Analysis
Auteur:
Choi, Michael Jamieson, Catriona Widhopf, George Yu, Jian Castro, Januario Kidwell, Reilly Li, Hongying Juarez, Tiffany Gorak, Susette Pittman, Emily Gutierrez, Charlene Rassenti, Laura Messer, Karen Prussak, Charles Kipps, Thomas